Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
Disease management
Health-related quality of life
Malignant pleural mesothelioma
Real-world
Treatment
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
23 Jun 2022
23 Jun 2022
Historique:
received:
03
02
2022
accepted:
25
05
2022
entrez:
23
6
2022
pubmed:
24
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive and rare tumour with poor prognosis. Most patients are diagnosed with advanced disease and there is a paucity of data on the humanistic burden of MPM in terms of impact on health-related quality of life (HRQoL) and activity. This study examined real-world treatment patterns and humanistic disease burden of MPM in Europe. Physicians abstracted demographic/clinical characteristics and treatment data from MPM-patient medical records; MPM patients self-completed a questionnaire including symptoms, 3-level-EQ-5D questionnaire and Visual Analogue Scale (VAS), Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso), and Work Productivity and Activity Impairment (WPAI) questionnaire. Physicians (n = 171) abstracted data of 1390 patients; 767/1390 patients self-completed questionnaires. Patients were elderly with advanced, unresectable MPM. Treatment patterns followed guidelines with most (81%) patients receiving platinum+antifolate chemotherapy at first line (1 L). Maintenance treatment use was high (51.1%) despite no recommended maintenance therapies. Symptom burden was high and health states and HRQoL were poor at 1; declining further with progression. Overall mean (SD): LCSS-Average Symptom Burden Index score was 48.8 (19.3; n = 758); EQ-5D Utility Index score was 0.510 (0.349; n = 763); EQ-5D VAS score was 54.2 (20.3;n = 766); LCSS-3-Item Global Index score was 143.2 (64.5; n = 762); LCSS-normal activities score was 51.9 (24.6;n = 765); WPAI-activity impairment was 56.0% (23.2%; n = 737). The humanistic burden of MPM is high, despite treatments being prescribed as per available guidance. Treatments that delay progression and provide palliation of symptoms are most likely to improve/maintain HRQoL.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pleural mesothelioma (MPM) is an aggressive and rare tumour with poor prognosis. Most patients are diagnosed with advanced disease and there is a paucity of data on the humanistic burden of MPM in terms of impact on health-related quality of life (HRQoL) and activity. This study examined real-world treatment patterns and humanistic disease burden of MPM in Europe.
METHODS
METHODS
Physicians abstracted demographic/clinical characteristics and treatment data from MPM-patient medical records; MPM patients self-completed a questionnaire including symptoms, 3-level-EQ-5D questionnaire and Visual Analogue Scale (VAS), Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso), and Work Productivity and Activity Impairment (WPAI) questionnaire.
RESULTS
RESULTS
Physicians (n = 171) abstracted data of 1390 patients; 767/1390 patients self-completed questionnaires. Patients were elderly with advanced, unresectable MPM. Treatment patterns followed guidelines with most (81%) patients receiving platinum+antifolate chemotherapy at first line (1 L). Maintenance treatment use was high (51.1%) despite no recommended maintenance therapies. Symptom burden was high and health states and HRQoL were poor at 1; declining further with progression. Overall mean (SD): LCSS-Average Symptom Burden Index score was 48.8 (19.3; n = 758); EQ-5D Utility Index score was 0.510 (0.349; n = 763); EQ-5D VAS score was 54.2 (20.3;n = 766); LCSS-3-Item Global Index score was 143.2 (64.5; n = 762); LCSS-normal activities score was 51.9 (24.6;n = 765); WPAI-activity impairment was 56.0% (23.2%; n = 737).
CONCLUSION
CONCLUSIONS
The humanistic burden of MPM is high, despite treatments being prescribed as per available guidance. Treatments that delay progression and provide palliation of symptoms are most likely to improve/maintain HRQoL.
Identifiants
pubmed: 35739480
doi: 10.1186/s12885-022-09750-7
pii: 10.1186/s12885-022-09750-7
pmc: PMC9229520
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
693Informations de copyright
© 2022. The Author(s).
Références
J Palliat Care. 2021 Apr;36(2):113-120
pubmed: 32791881
Respirology. 2005 Jan;10(1):2-8
pubmed: 15691231
Lung Cancer. 2015 Jun;88(3):344-8
pubmed: 25863904
Cancer. 1994 Apr 15;73(8):2087-98
pubmed: 8156514
Eur J Cancer Care (Engl). 2010 Jul;19(4):458-68
pubmed: 19832887
Neuropsychiatr Dis Treat. 2013;9:1193-202
pubmed: 23983468
Eur Respir Rev. 2016 Dec;25(142):472-486
pubmed: 27903668
J Thorac Oncol. 2008 Jul;3(7):764-71
pubmed: 18594323
J Clin Oncol. 2018 May 1;36(13):1343-1373
pubmed: 29346042
Ochsner J. 2012 Spring;12(1):70-9
pubmed: 22438785
Front Psychol. 2018 Feb 20;9:205
pubmed: 29515509
Ann Transl Med. 2015 Aug;3(13):182
pubmed: 26366399
J Thorac Oncol. 2008 Jul;3(7):756-63
pubmed: 18594322
Support Care Cancer. 2014 Jan;22(1):181-7
pubmed: 24026981
BMC Cancer. 2015 Nov 06;15:857
pubmed: 26546402
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Ann Oncol. 2015 Sep;26 Suppl 5:v31-9
pubmed: 26223247
Pak J Med Sci. 2013 Nov;29(6):1433-8
pubmed: 24550969
Clin Lung Cancer. 2020 Nov;21(6):553-561.e1
pubmed: 32727707
Support Care Cancer. 1999 May;7(3):140-8
pubmed: 10335932
J Thorac Oncol. 2006 Jan;1(1):25-30
pubmed: 17409823
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32451346
Qual Life Res. 2019 Jul;28(7):1849-1861
pubmed: 30825160
Lung Cancer. 2020 Sep;147:83-90
pubmed: 32682189
Medicine (Baltimore). 2016 Apr;95(14):e3351
pubmed: 27057918
Br J Cancer. 2015 Mar 31;112(7):1183-9
pubmed: 25756395
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
J Thorac Oncol. 2018 Feb;13(2):194-204
pubmed: 29129758
Health Qual Life Outcomes. 2010 Sep 21;8:104
pubmed: 20858248
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669